In the pre-Rituximab era, Takubo et al. classified NHL patients based on their IL-18 serum levels before treatment with cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone (CHOP) and compared the outcomes between patients with IL-18 serum levels >2000 pg/mL and those with IL-18 serum levels <1000 pg/mL, reporting statistically significant lower complete remission (CR) rates (33.3% versus 85.7%) and lower median overall survival (OS) (3.5 months versus 45.5 months) for the former group [84]. The gene discussed is IL18; the disease is non-Hodgkin lymphoma.